TrialJNCI cancer spectrum2022

Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial.

Nicholas D James et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.